This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely delivered and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It is currently being tested to determine its effects on telomerase activity.